Compare Neurocrine Biosciences Inc (NBIX) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while iShares 0 3 Month Treasury Bond ETF trades at $100.49. Which is the better fit depends on your goals.
| NBIX | SGOV | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | Fixed Income |
52-Week High | $185.50 | $100.72 |
52-Week Low | $123.10 | $100.28 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SGOV trades at $100.475 with minimal daily movement, showing price stability amid bearish technical signals. The ETF maintains consistent dividend distributions with recent payouts of $0.30-$0.31 per share. Technical indicators show strong bearish momentum with 17 sell signals versus 3 buy signals, though RSI levels suggest potential oversold conditions. Market sentiment reflects broader Treasury market concerns as rising oil prices fuel inflation worries.
The outlook remains cautious given the bearish technical picture and macroeconomic headwinds from rising Treasury yields. Investors seeking Treasury exposure may find value in SGOV's stability and dividend consistency, though the current environment of rising rates and inflation pressures presents near-term challenges for fixed income ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
